Second Round of Late-Breaking Clinical Trial Results Announced at VIVA23
Retrieved on:
Tuesday, October 31, 2023
Blood vessel, Patient, Angiography, Isabella Tree, Peripheral artery disease, PTA, De novo, Artery, Education, Incidence, DCB, Ioctl, BMI, AVF, CLTI, Kaplan–Meier estimator, Kidney disease, Research, HIV disease progression rates, RCT, Wound healing, BRS, Dialysis, Thrombosis, Clinical trial, Extremities, Risk, Dural arteriovenous fistula, Magnitude, Classification, VIVA, IVUS, Amputation, BTK, PAD, Wynn Las Vegas, Infection, Medical imaging, Pharmaceutical industry, Silviculture
Below are highlights of this afternoon's 3 late-breaking clinical trial presentations.
Key Points:
- Below are highlights of this afternoon's 3 late-breaking clinical trial presentations.
- Results from Abbott's LIFE-BTK randomized clinical trial (RCT) demonstrate that Esprit BTK (Abbott) reduces disease progression and helps improve medical outcomes compared to balloon angioplasty, the current state of care.
- In the LIFE-BTK trial, wound assessment was not a prespecified powered primary or secondary endpoint but rather a prespecified descriptive endpoint.
- The trial offers the largest ischemic wound data set to date, collected systematically and adjudicated independently in a blinded fashion.